| Status | In progress |
| Process | STA |
| ID number | 951 |
Provisional Schedule
| Committee meeting: 1 | 08 August 2017 |
| Expected publication | 28 February 2018 |
Project Team
| Project lead | Liv Gualda |
Email enquiries
- If you have any queries please email TACommA@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 March 2017 | The appraisal of fulvestrant for untreated hormone-receptor positive metastatic breast cancer [ID951] has been rescheduled following an update on regulatory timings from the company. The first committee meeting will now take place on 08 August 2017. |
| 13 December 2016 | Invitation to participate |
| 08 June 2016 | Referral |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance